The Effect Of Wuzhi Capsules On The Concentration Of Tacrolimus In Kidney Transplant Patients

【Objective】To investigate the effect of Wuzhi capsules on concentration of Tacrolimus in kidney transplant patients with poor absorption and to provide evidence for clinical individual dosage.【Methods】1) Forty-two kidney transplant patients who were taking high-dose FK506 but with lower blood concentration were orally administered with Wuzhi capsules(1 capsule each,twice a day);2) The changes in the concentration of FK506 were observed one week later , and the dosage of FK506 were adjusted according to the therapeutic window ;3) The correlation of the dosage with the concentration of FK506 was analyzed. The occurrence of liver,kidney dysfunction and acute rejection were recorded at the first, second, third, sixth and twelfth month.【Results】1) Compared to pre-coadministration of Wuzhi capsules,the patients had increased tough levels of FK506 of 262% in average after one week.2) The dosage of FK506 in one year follow-up were significantly reduced and the concentration of FK506 were well controlled between 5 to 10 ng·mL-1. 3) There was no obvious dysfunction in liver and kidney, and no acute rejection was observed.【Conclusion】Wuzhi capsules is an effective,safe and stable drug, assisted to raise the blood concentration of FK506. It is also a good treatment option for kidney transplant patients with poor absorption.